Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-017730

PRESIDENT AND CEO sold 12,500 shares at an average $22.18 ($277,292)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Kintz Samuel PRESIDENT AND CEO 2025-06-17 Sale 10b5-1 −10,502 $22.08 $231,839 954,890 I: show line 1 in the form
Kintz Samuel PRESIDENT AND CEO 2025-06-17 Sale 10b5-1 −1,998 $22.75 $45,453 952,892 I: show line 2 in the form
Open-market sales · 12,500 sh · avg $22.18 · $277,292
Loading xslF345X05/form4-06182025_100643.xml…